Literature DB >> 21437686

Clinical features and independent predictors of pulmonary arterial hypertension in systemic lupus erythematosus.

Fan Lian1, Dongying Chen, Yu Wang, Yujin Ye, Xiaodong Wang, Zhongping Zhan, Hanshi Xu, Liuqin Liang, Xiuyan Yang.   

Abstract

Pulmonary arterial hypertension (PAH) is a devastating complication of systemic lupus erythematosus (SLE). We aim to estimate the putative predictors contributing to early identification of PAH, thus improve appropriate medical intervention and a better prognosis. A retrospective case-control study was conducted. Forty-one SLE patients with PAH and 106 SLE patients without PAH were enrolled. Demographic variables, clinical features, and laboratory data were compared between the two groups. Univariate and multivariate logistic regression models were used to examine the predictors contributing to PAH in SLE. Serositis, Raynaud's phenomenon, high disease activity, anticardiolipin antibodies, and anti-U1RNP were significantly associated with SLE-PAH. Univariate and multivariate analysis showed that Raynaud's phenomenon, anticardiolipin antibodies, and anti-U1RNP were independent predictors of PAH in SLE. This study highlighted the clinical pattern of SLE-PAH patients, and underlined the leading predictors of PAH development among patients with SLE. Routine echocardiography is recommended in SLE patients with the independent predictors mentioned above.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21437686     DOI: 10.1007/s00296-011-1880-4

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   3.580


  31 in total

Review 1.  Prognosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines.

Authors:  Vallerie V McLaughlin; Kenneth W Presberg; Ramona L Doyle; Steven H Abman; Douglas C McCrory; Terry Fortin; Gregory Ahearn
Journal:  Chest       Date:  2004-07       Impact factor: 9.410

2.  Raynaud's phenomenon is correlated with elevated systolic pulmonary arterial pressure in patients with systemic lupus erythematosus.

Authors:  A Kasparian; A Floros; E Gialafos; M Kanakis; S Tassiopoulos; N Kafasi; G Vaiopoulos
Journal:  Lupus       Date:  2007       Impact factor: 2.911

3.  Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology.

Authors:  Nazzareno Galiè; Adam Torbicki; Robyn Barst; Philippe Dartevelle; Sheila Haworth; Tim Higenbottam; Horst Olschewski; Andrew Peacock; Giuseppe Pietra; Lewis J Rubin; Gerald Simonneau; Silvia G Priori; Maria Angeles Alonso Garcia; Jean-Jacques Blanc; Andrzej Budaj; Martin Cowie; Verconcia Dean; Jaap Deckers; Enrique Fernandez Burgos; John Lekakis; Bertil Lindahl; Gianfranco Mazzotta; Keith McGregor; João Morais; Ali Oto; Otto A Smiseth; Joan Albert Barbera; Simon Gibbs; Marius Hoeper; Marc Humbert; Robert Naeije; Joanna Pepke-Zaba
Journal:  Eur Heart J       Date:  2004-12       Impact factor: 29.983

4.  Pulmonary arterial hypertension in France: results from a national registry.

Authors:  Marc Humbert; Olivier Sitbon; Ari Chaouat; Michèle Bertocchi; Gilbert Habib; Virginie Gressin; Azzedine Yaici; Emmanuel Weitzenblum; Jean-François Cordier; François Chabot; Claire Dromer; Christophe Pison; Martine Reynaud-Gaubert; Alain Haloun; Marcel Laurent; Eric Hachulla; Gérald Simonneau
Journal:  Am J Respir Crit Care Med       Date:  2006-02-02       Impact factor: 21.405

5.  Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study.

Authors:  Eric Hachulla; Virginie Gressin; Loïc Guillevin; Patrick Carpentier; Elisabeth Diot; Jean Sibilia; André Kahan; Jean Cabane; Camille Francès; David Launay; Luc Mouthon; Yannick Allanore; Kiet Phong Tiev; Pierre Clerson; Pascal de Groote; Marc Humbert
Journal:  Arthritis Rheum       Date:  2005-12

Review 6.  Pulmonary hypertension, antiphospholipid antibodies, and syndromes.

Authors:  Ronald A Asherson; Ricard Cervera
Journal:  Clin Rev Allergy Immunol       Date:  2007-04       Impact factor: 8.667

7.  Anti-topoisomerase I (anti-Scl-70) antibodies in patients with systemic lupus erythematosus.

Authors:  H A Gussin; G P Ignat; J Varga; M Teodorescu
Journal:  Arthritis Rheum       Date:  2001-02

8.  Immunopathologic and clinical studies in pulmonary hypertension associated with systemic lupus erythematosus.

Authors:  F P Quismorio; O Sharma; M Koss; T Boylen; A W Edmiston; P J Thornton; D Tatter
Journal:  Semin Arthritis Rheum       Date:  1984-05       Impact factor: 5.532

9.  Clinical aspects of pulmonary hypertension in patients with systemic lupus erythematosus and in patients with idiopathic pulmonary arterial hypertension.

Authors:  Son-Mi Chung; Chang-Keun Lee; Eun Young Lee; Bin Yoo; Sang-Do Lee; Hee-Bom Moon
Journal:  Clin Rheumatol       Date:  2006-02-22       Impact factor: 2.980

Review 10.  Vasculopathy and pulmonary arterial hypertension.

Authors:  L Guillevin
Journal:  Rheumatology (Oxford)       Date:  2009-06       Impact factor: 7.580

View more
  15 in total

Review 1.  Screening and diagnostic modalities for connective tissue disease-associated pulmonary arterial hypertension: a systematic review.

Authors:  Heather Gladue; Nezam Altorok; Whitney Townsend; Vallerie McLaughlin; Dinesh Khanna
Journal:  Semin Arthritis Rheum       Date:  2013-09-05       Impact factor: 5.532

Review 2.  Pulmonary hypertension associated with antiphospholipid antibody: Call for a screening tool?

Authors:  Rukma Parthvi; Rutuja R Sikachi; Abhinav Agrawal; Ajay Adial; Abhinav Vulisha; Sameer Khanijo; Arunabh Talwar
Journal:  Intractable Rare Dis Res       Date:  2017-08

3.  Is there a difference in systemic lupus erythematosus with and without Raynaud's phenomenon?

Authors:  Slavica Pavlov-Dolijanovic; Nemanja S Damjanov; Nada Z Vujasinovic Stupar; Danijel R Marcetic; Mirjana N Sefik-Bukilica; Radmila R Petrovic
Journal:  Rheumatol Int       Date:  2012-05-22       Impact factor: 2.631

Review 4.  Pulmonary hypertension in antiphospholipid syndrome.

Authors:  Stéphane Zuily; Denis Wahl
Journal:  Curr Rheumatol Rep       Date:  2015-01       Impact factor: 4.592

5.  Asymptomatic pulmonary hypertension in systemic lupus erythematosus.

Authors:  Shereen R Kamel; Gihan M Omar; Ayman F Darwish; Hany T Asklany; Abdou S Ellabban
Journal:  Clin Med Insights Arthritis Musculoskelet Disord       Date:  2011-09-28

Review 6.  Pulmonary arterial hypertension in systemic lupus erythematosus: current status and future direction.

Authors:  Atiya Dhala
Journal:  Clin Dev Immunol       Date:  2012-03-22

7.  Pulmonary hypertension in systemic lupus erythematosus: an independent predictor of patient survival.

Authors:  Hong Ki Min; Jae Ho Lee; Seung Min Jung; Jennifer Lee; Kwi Young Kang; Seung-Ki Kwok; Ji Hyeon Ju; Kyung-Su Park; Sung-Hwan Park
Journal:  Korean J Intern Med       Date:  2015-02-27       Impact factor: 2.884

8.  Baseline Characteristics and Risk Factors of Pulmonary Arterial Hypertension in Systemic Lupus Erythematosus Patients.

Authors:  Can Huang; Mengtao Li; Yongtai Liu; Qian Wang; Xiaoxiao Guo; Jiuliang Zhao; Jinzhi Lai; Zhuang Tian; Yan Zhao; Xiaofeng Zeng
Journal:  Medicine (Baltimore)       Date:  2016-03       Impact factor: 1.889

Review 9.  Systemic lupus erythematosus and pulmonary arterial hypertension: links, risks, and management strategies.

Authors:  Konstantinos Tselios; Dafna D Gladman; Murray B Urowitz
Journal:  Open Access Rheumatol       Date:  2016-12-20

10.  Mycophenolate Mofetil in a Lupus Patient with Pulmonary Hypertension.

Authors:  Kirthi Machireddy; Zin Myint; Eric Dein; Stephen C Mathai; Philip Seo; Uzma Haque; Rebecca Manno; Homa Timlin
Journal:  Cureus       Date:  2018-01-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.